Selected article for: "computational approach and drug repurposing"
Author: Sugiyama, Michael G.; Cui, Haotian; Redka, Dar’ya S.; Karimzadeh, Mehran; Rujas, Edurne; Maan, Hassaan; Hayat, Sikander; Cheung, Kyle; Misra, Rahul; McPhee, Joseph B.; Viirre, Russell D.; Haller, Andrew; Botelho, Roberto J.; Karshafian, Raffi; Sabatinos, Sarah A.; Fairn, Gregory D.; Tonekaboni, Seyed Ali Madani; Windemuth, Andreas; Julien, Jean-Philippe; Shahani, Vijay; MacKinnon, Stephen S.; Wang, Bo; Antonescu, Costin N.
Title: Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease
  • Cord-id: ohfqkvas
  • Document date: 2021_4_13
    • ID: ohfqkvas
    Snippet: The COVID-19 pandemic has led to an urgent need for the identification of new antiviral drug therapies that can be rapidly deployed to treat patients with this disease. COVID-19 is caused by infection with the human coronavirus SARS-CoV-2. We developed a computational approach to identify new antiviral drug targets and repurpose clinically-relevant drug compounds for the treatment of COVID-19. Our approach is based on graph convolutional networks (GCN) and involves multiscale host-virus interact
    Document: The COVID-19 pandemic has led to an urgent need for the identification of new antiviral drug therapies that can be rapidly deployed to treat patients with this disease. COVID-19 is caused by infection with the human coronavirus SARS-CoV-2. We developed a computational approach to identify new antiviral drug targets and repurpose clinically-relevant drug compounds for the treatment of COVID-19. Our approach is based on graph convolutional networks (GCN) and involves multiscale host-virus interactome analysis coupled to off-target drug predictions. Cellbased experimental assessment reveals several clinically-relevant repurposing drug candidates predicted by the in silico analyses to have antiviral activity against human coronavirus infection. In particular, we identify the MET inhibitor capmatinib as having potent and broad antiviral activity against several coronaviruses in a MET-independent manner, as well as novel roles for host cell proteins such as IRAK1/4 in supporting human coronavirus infection, which can inform further drug discovery studies.

    Search related documents:
    Co phrase search for related documents
    • activation function and adaptive immune response: 1, 2, 3, 4
    • activation function and adaptor protein: 1
    • activation function and local global: 1
    • activation function and loss function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • activation function relu and loss function: 1
    • acute respiratory syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and adaptor protein: 1, 2, 3, 4, 5
    • acute respiratory syndrome and additional drug: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and adjacent cell: 1, 2
    • acute respiratory syndrome and live virus infection: 1, 2, 3, 4, 5
    • acute respiratory syndrome and local global: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and loss function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adaptive immune response and additional drug: 1
    • adaptive immune response and loss function: 1
    • adaptor protein and loss function: 1